NRX Pharmaceuticals Inc
NRXP2.970USD
-0.010-0.34%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
57.84MCap. mercado
PérdidaP/E TTM
Más Datos de NRX Pharmaceuticals Inc Compañía
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Información de la empresa
Símbolo de cotizaciónNRXP
Nombre de la empresaNRX Pharmaceuticals Inc
Fecha de salida a bolsaNov 20, 2017
Director ejecutivoDr. Jonathan C. Javitt, M.D.
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 20
Dirección1201 Orange Street
CiudadWILMINGTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal19801
Teléfono14842546134
Sitio Webhttps://www.nrxpharma.com/
Símbolo de cotizaciónNRXP
Fecha de salida a bolsaNov 20, 2017
Director ejecutivoDr. Jonathan C. Javitt, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan C. Javitt, M.D.
Dr. Jonathan C. Javitt, M.D.
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
1.52M
-0.01%
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
221.48K
--
Mr. Michael (Mike) Taylor
Mr. Michael (Mike) Taylor
Independent Director
Independent Director
--
--
Mr. Patrick J. Flynn
Mr. Patrick J. Flynn
Independent Director
Independent Director
--
--
Mr. Riccardo (Rick) Panicucci
Mr. Riccardo (Rick) Panicucci
Chief Manufacturing and Technology Officer
Chief Manufacturing and Technology Officer
--
--
Mr. Michael S. (Mike) Abrams
Mr. Michael S. (Mike) Abrams
Chief Financial Officer and Treasurer
Chief Financial Officer and Treasurer
--
--
Dr. Dennis Mcbride
Dr. Dennis Mcbride
Independent Director
Independent Director
--
--
Mr. Matthew P. Duffy
Mr. Matthew P. Duffy
Chief Business Officer
Chief Business Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jonathan C. Javitt, M.D.
Dr. Jonathan C. Javitt, M.D.
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
1.52M
-0.01%
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
221.48K
--
Mr. Michael (Mike) Taylor
Mr. Michael (Mike) Taylor
Independent Director
Independent Director
--
--
Mr. Patrick J. Flynn
Mr. Patrick J. Flynn
Independent Director
Independent Director
--
--
Mr. Riccardo (Rick) Panicucci
Mr. Riccardo (Rick) Panicucci
Chief Manufacturing and Technology Officer
Chief Manufacturing and Technology Officer
--
--
Mr. Michael S. (Mike) Abrams
Mr. Michael S. (Mike) Abrams
Chief Financial Officer and Treasurer
Chief Financial Officer and Treasurer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: lun., 25 de ago
Actualizado: lun., 25 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
B Group, Inc.
12.62%
Anson Funds Management LP.
6.75%
Javitt (Jonathan C)
6.38%
Glytech LLC
4.05%
The Vanguard Group, Inc.
1.90%
Otro
68.29%
Accionistas
Accionistas
Proporción
B Group, Inc.
12.62%
Anson Funds Management LP.
6.75%
Javitt (Jonathan C)
6.38%
Glytech LLC
4.05%
The Vanguard Group, Inc.
1.90%
Otro
68.29%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
16.74%
Individual Investor
7.50%
Hedge Fund
7.28%
Corporation
4.05%
Investment Advisor/Hedge Fund
1.39%
Research Firm
0.06%
Otro
62.98%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
66
5.07M
29.31%
+1.44M
2025Q1
66
4.06M
26.08%
+505.82K
2024Q4
70
3.94M
22.32%
-356.61K
2024Q3
83
3.57M
28.23%
-628.46K
2024Q2
86
3.38M
32.03%
-634.67K
2024Q1
92
3.27M
34.30%
-835.14K
2023Q4
98
3.31M
81.28%
-805.62K
2023Q3
101
3.31M
42.19%
-663.76K
2023Q2
103
3.89M
52.92%
+527.79K
2023Q1
100
3.14M
46.14%
-970.16K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Anson Funds Management LP.
1.18M
6.82%
+993.40K
+535.06%
Mar 31, 2025
Javitt (Jonathan C)
1.52M
8.77%
-199.00
-0.01%
Apr 29, 2025
Glytech LLC
963.48K
5.57%
+963.48K
--
Apr 29, 2025
The Vanguard Group, Inc.
388.93K
2.25%
+148.61K
+61.84%
Mar 31, 2025
AdvisorShares Investments, LLC
286.80K
1.66%
-23.52K
-7.58%
Mar 31, 2025
Hurvitz (Chaim)
221.48K
1.28%
+1.00
+0.00%
Apr 29, 2025
Geode Capital Management, L.L.C.
134.66K
0.78%
+60.41K
+81.35%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Fecha
Tipo
Relación
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
Mar 28, 2024
Merger
10→1
